Ulcerative Colitis Market Report 2025 (Global Edition)

Global Ulcerative Colitis Market Report 2024 Market Size Split by Disease Type (Mild UC, Moderate UC, Severe UC), by Molecule Type (Biologics, Small Molecules), by Route of Administration (Oral, Injec...

Ulcerative Colitis Market Report Description

We have various report editions of Ulcerative Colitis Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Ulcerative Colitis Market Insights Video

Competitive Landscape of the Ulcerative Colitis Market

Major companies in the fiercely competitive ulcerative colitis industry include AbbVie, Johnson & Johnson, Pfizer, and Takeda Pharmaceuticals. These businesses are industry leaders in biologics, producing Entyvio, Remicade, and Humira. The emergence of biosimilars and cutting-edge treatments like Janus kinase (JAK) inhibitors has increased competition. Competition is further fueled by ongoing R&D and clinical trials for novel treatments as businesses search for creative, more efficient ways to manage the illness.

In April 2023, Merck & Co., Inc. agreed to acquire Prometheus Biosciences for USD 200.00 in cash per share, or an estimated USD 10.8 billion in equity value. By this agreement, Prometheus Biosciences may now fully realize the potential of PRA023, a novel late-stage candidate for the treatment of Crohn's disease, ulcerative colitis, and other autoimmune illnesses. (Source:https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/) In March 2023, The Ministry of Labor, Welfare, and Health of Japan approved Takeda Pharmaceutical Company Limited's Entyvio Pens (vedolizumab) maintenance treatment for moderate-to-severe ulcerative colitis. (Source: https://www.takeda.com/newsroom/newsreleases/2023/approval-to-manufacture-and-market-entyvio/) In December 2022, According to Pfizer Inc., the FDA in the United States approved the new drug application (NDA) for etrasimod for individuals with mildly to highly active ulcerative colitis. (Source:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-fda-and-ema-acceptance-etrasimod)

Top Companies Market Share in Ulcerative Colitis Industry: (In no particular order of Rank)

• AbbVie Inc. (Allergan
• Inc.)
• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd
• Johnson & Johnson
• Merck & Co.
• Inc.
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Mitsubishi Tanabe Pharma Corporation
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Bristol Myers Squibb
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Ulcerative Colitis Market

Which Region Dominates the Ulcerative Colitis Market in 2024?

According to Cognitive Market Research, North America currently dominates the Ulcerative Colitis market, and the region is expected to have significant growth during the projected period. The market for ulcerative colitis is expected to grow highest in North America because of the region's high prevalence of the illness, sophisticated healthcare system, and growing use of biologics and cutting-edge treatments. Early diagnosis and efficient treatment are made possible by the area's sophisticated healthcare system and high levels of awareness regarding gastrointestinal illnesses. In addition, substantial funding for research and development, especially in the United States, promotes the release of novel therapies like Janus kinase (JAK) inhibitors. As the market expands in North America, favorable reimbursement rules and growing demand for personalized medicine position it as a major worldwide growth driver.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The market for ulcerative colitis is expected to increase in the Asia Pacific area as a result of rising awareness of gastrointestinal disorders, improved healthcare infrastructure, and rising prevalence of the condition. The rapid economic expansion and urbanization of nations like China and India cause higher incidence rates and a larger need for cutting-edge treatments. The government's efforts to enhance healthcare services and the increase of healthcare access encourage early diagnosis and treatment. Furthermore, this region's market is expanding more quickly due to rising R&D spending and the launch of innovative treatments, including biologics and JAK inhibitors.

The current report Scope analyzes Ulcerative Colitis Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Ulcerative Colitis Market

According to Cognitive Market Research, the global Ulcerative Colitis market size was estimated at USD 715.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 286.20 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Ulcerative Colitis market with a market size of USD 225.81 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. The increasing frequency of ulcerative colitis in the United States is fueling the need for cutting-edge therapy.
• The Canadian ulcerative Colitis market had a market share of USD 34.34 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. The adoption of cutting-edge treatment options and continuous research into ulcerative colitis are supported by Canada's robust healthcare system.
• The Mexico Ulcerative Colitis market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 26.04 million in 2024.

Europe Ulcerative Colitis Market

According to Cognitive Market Research, the global Ulcerative Colitis market size was estimated at USD 715.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 214.65 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031.

• The United Kingdom Ulcerative Colitis market had a market share of USD 36.06 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. In the UK, market expansion is aided by NHS programs that enhance the diagnosis, treatment, and management of chronic conditions like ulcerative colitis.
• The France Ulcerative Colitis market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 19.75 million in 2024.
• According to Cognitive Market Research, the German Ulcerative Colitis market size was valued at USD 42.50 million in 2024 and is projected to grow at a CAGR of 5.7% during the forecast period. The development of novel treatments and modalities for ulcerative colitis is facilitated by Germany's emphasis on medical innovation and research.
• The Italy Ulcerative Colitis market is projected to witness growth at a CAGR of 4.9% during the forecast period, with a market size of USD 18.46 million in 2024.
• The Russia Ulcerative Colitis market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 33.27 million in 2024.
• The Spain Ulcerative Colitis market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 17.60 million in 2024
• The Luxembourg Ulcerative Colitis market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 6.65 million in 2024.
• The Portugal Ulcerative Colitis market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 4.51 million in 2024.
• The Greece Ulcerative Colitis market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 2.58 million in 2024.
• The Rest of Europe's Ulcerative Colitis market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 33.27 million in 2024.

Asia Pacific Ulcerative Colitis Market

According to Cognitive Market Research, the global Ulcerative Colitis market size was estimated at USD 715.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 164.57 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Ulcerative Colitis market size was valued at USD 74.05 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period. Ulcerative Colitis surged in China due to the demand for better treatment alternatives driven by the rising incidence of ulcerative colitis in China, which is partially attributable to changes in lifestyle.
• The Japan Ulcerative Colitis market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 22.71 million in 2024.
• The India Ulcerative Colitis market had a market share of USD 19.75 million in 2024 and is projected to grow at a CAGR of 10.8% during the forecast period. In India, the market is expanding as a result of government health efforts and programs that improve access to treatments and gastrointestinal health.
• The South Korean Ulcerative Colitis market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 16.46 million in 2024.
• The Australian Ulcerative Colitis market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 8.56 million in 2024.
• The South East Asia Ulcerative Colitis market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 11.35 million in 2024.
• The Rest of Asia Pacific Ulcerative Colitis market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 11.68 million in 2024.

South America Ulcerative Colitis Market

According to Cognitive Market Research, the global Ulcerative Colitis market size was estimated at USD 715.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 35.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Ulcerative Colitis market size was valued at USD 15.31 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. Ulcerative Colitis flourished in Brazil. The market is expanding because of regulatory policies that are supportive and streamlined approval procedures for novel UC medicines.
• Argentina's Ulcerative Colitis market had a market share of USD 6.01 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. In Argentina, there is a greater need for ulcerative colitis therapies and a higher diagnosis rate due to enhanced diagnostic capabilities and more awareness.
• Colombia's Ulcerative Colitis market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 3.18 million in 2024.
• Peru Ulcerative Colitis market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD 2.93 million in 2024.
• Chile's Ulcerative Colitis market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 2.58 million in 2024.
• The Rest of Latin America's Ulcerative Colitis market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 5.76 million in 2024.

Middle East and Africa Ulcerative Colitis Market

According to Cognitive Market Research, the global Ulcerative Colitis market size was estimated at USD 715.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 14.31 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031..

• The GCC Countries Ulcerative Colitis market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 6.12 million in 2024. Ulcerative Colitis sales flourish due to the presence of major market players.
• The Egypt Ulcerative Colitis market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 1.50 million in 2024.
• The South African ulcerative Colitis market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 2.26 million in 2024. South Africa is becoming a hub for UC therapy clinical trials, which is driving innovation and expanding the market.
• The Turkey Ulcerative Colitis market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 1.23 million in 2024.
• The Nigeria Ulcerative Colitis market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 1.50 million in 2024.
• The Rest of the MEA Ulcerative Colitis market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 1.69 million in 2024.

Ulcerative Colitis Market Analysis

Ulcerative Colitis Market Disease Type Segment Analysis

According to Cognitive Market Research, mild UC is likely to dominate the Ulcerative Colitis Market over the forecast period. Healthcare professionals are seeking to effectively manage and control less severe types of ulcerative colitis (UC), which is driving up demand for medicines targeting UC disease. As a result, oral drugs such as aminosalicylates and certain corticosteroids, which are less expensive, are more frequently used by patients with mild UC than by those with moderate to severe types. Growing market demand for customized, affordable therapies is fueled by improved awareness and early diagnosis, which also lead to a stronger emphasis on treating minor instances.

The moderate UC is the fastest-growing segment in the Ulcerative Colitis Market. Because more severe cases of ulcerative colitis (UC) require proper management, there is an increasing demand for medicines aimed at treating this kind of illness. Patients with moderate UC frequently need a mix of treatments, such as biologics like TNF inhibitors and integrin inhibitors, as well as oral drugs like corticosteroids and immunosuppressants. The need for cutting-edge treatment alternatives is driven by the emphasis on attaining remission and reducing inflammation. The market for moderate UC medicines keeps growing as early diagnosis and disease management become more well-known, meeting the needs of a sizable patient population.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Ulcerative Colitis Industry. Request a Free Sample PDF!

Ulcerative Colitis Market Molecule Type Segment Analysis

According to Cognitive Market Research, the biologics segment holds the largest share of the market. Because biologic therapies are so successful at treating moderate-to-severe instances of ulcerative colitis, there is a rising market for them. By focusing on particular inflammatory pathways, biologics such as TNF inhibitors (e.g., Humira, Remicade), integrin inhibitors (e.g., Entyvio), and interleukin inhibitors provide focused treatment. Their considerable demand stems from their capacity to improve quality of life and achieve remission. The market for biologic molecules in ulcerative colitis keeps growing as new biologic medicines and biosimilars appear, providing creative options and competitive pricing.

In the Ulcerative Colitis Market, the small molecules have been expanding at a rapid pace. Because small molecules can be taken orally and efficiently manage the symptoms of the disease, there is a growing market for them in ulcerative colitis. For the treatment of moderate to severe ulcerative colitis, small molecules like Janus kinase (JAK) inhibitors like Xeljanz and Rinvoq are an efficient and convenient substitute for injectable biologics. Their increasing use is fueled by their ability to reduce inflammation and offer a focused method of managing illnesses. With the growing market for these therapies, patients looking for less invasive, more effective treatment choices have intriguing possibilities at their disposal.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Ulcerative Colitis Route of Administration Segment Analysis

Ulcerative Colitis Market Route of Administration Segment Analysis

According to Cognitive Market Research, the oral segment holds the largest market share. Because oral medications are more convenient and straightforward to administer than injectable therapy, there is an increasing market demand for them in the ulcerative colitis market. For patients seeking a more controlled and minimally intrusive means of managing their symptoms and reaching remission, oral drugs, such as aminosalicylates and small molecules like Janus kinase (JAK) inhibitors, present an option. The promise of better adherence and less discomfort is what makes oral medications preferred. Effective oral therapies are becoming more widely available as the market grows, meeting the needs of patients looking for workable and efficient management alternatives.

In the Ulcerative Colitis market, the rapidly growing sector is the injectable category. Because injectable therapies are effective in treating moderate to severe cases of ulcerative colitis, there is still a high demand for them in the market. Biologics are essential for inducing remission and managing inflammation. Examples of these are integrin inhibitors (Entyvio) and TNF inhibitors (Humira, Remicade), which are usually injected. Injectables are recommended because of their targeted action and efficacy in situations where other therapies may not be sufficient, even though oral drugs are more convenient. The necessity for efficient management of ulcerative colitis and the development of innovative medications have led to a persistent growth in the market for injectable treatments.

• Oral
• Injectable

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion